Moolec Science SA Ordinary Shares (MLEC)vsMerck & Company Inc (MRK)
MLEC
Moolec Science SA Ordinary Shares
$7.03
-4.87%
HEALTHCARE · Cap: $5.18M
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 849764% more annual revenue ($66.57B vs $7.83M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MLEC earns a higher WallStSmart Score of 44/100 (D).
MLEC
Hold44
out of 100
Grade: D
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MLEC.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 948.0% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Trading at 10.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : MLEC
The strongest argument for MLEC centers on Revenue Growth. Revenue growth of 948.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : MLEC
The primary concerns for MLEC are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.21 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
MLEC profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.23 — expect wider price swings.
MLEC is growing revenue faster at 948.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MLEC scores higher overall (44/100 vs 36/100) and 948.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moolec Science SA Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company is headquartered in Luxembourg.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?